首页> 美国卫生研究院文献>Clinical Ophthalmology (Auckland N.Z.) >A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration

【2h】

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration

机译：前瞻性先导研究比较玻璃体内雷珠单抗和半定量光动力疗法与雷珠单抗单药联合治疗新血管性年龄相关性黄斑变性的疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThis prospective multi-center pilot study compares the use of half-fluence photodynamic therapy combined with ranibizumab with ranibizumab monotherapy for the treatment of neovascular age-related macular degeneration.

机译：目的这项前瞻性多中心先导研究比较了半通量光动力疗法与兰尼单抗联合兰尼单抗单药治疗新血管性年龄相关性黄斑变性的疗效。

著录项

期刊名称 Clinical Ophthalmology (Auckland N.Z.)
作者
Patrick D Williams; David Callanan; Wayne Solley; Robert L Avery; Dante J Pieramici; Tom Aaberg;
展开▼
作者单位

展开▼
年(卷),期 2012(6),-1
年度 2012
页码 1519–1525
总页数 7
原文格式 PDF
正文语种
中图分类眼科学;
关键词
ranibizumab macular degeneration photodynamic therapy verteporfin choroidal neovascularization anti-vegf;

机译：雷珠单抗;黄斑变性;光动力疗法;韦替泊芬;脉络膜新生血管;抗vegf;

相似文献

外文文献
中文文献
专利

1. A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration [J] . Patrick D Williams, David Callanan, Wayne Solley, Clinical ophthalmology . 2012,第4期

机译：前瞻性先导研究比较玻璃体内雷珠单抗和半定量光动力疗法与雷珠单抗单药联合治疗新血管性年龄相关性黄斑变性的疗效
2. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. [J] . Vallance JH, Johnson B, Majid MA, Eye . 2010,第10期

机译：比较光动力疗法与玻璃体内雷珠单抗与玻璃体内雷珠单抗单药联合治疗新血管性年龄相关性黄斑变性的随机前瞻性双盲探索性研究。
3. Clinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular DegenerationClinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular Degeneration [J] . Elman Michael J., Brown David M., Kaiser Peter K., Investigative ophthalmology & visual science . 2018,第9期

机译：与Ranibizimab双药草的治疗幼鱼乳蛋白单疗法与Ranibizimab与ranibizimab与Ranibizimab单疗法相比，与Ranibizimab的单一治疗与Ranibizimab双胍溶解的临床研究与Ranibizimab Ophthalmic溶液相比，与Ranibizimab的治疗中的治疗中的幼苗单一治疗相比，临床研究与Ranibizimizumab相比。退化
4. Expression Pattern of Kinin-Dependent Genes in Peripheral Blood Mononuclear Cells After Age-Related Macular Degeneration Treatment with Ranibizumab [C] . Michalska-Malecka K, Strzalka-Mrozik B., Kimsa M.W., International Symposium on Ocular Pharmacology and Therapeutics . 2013

机译：与RANIBIZIMAB的年龄相关黄斑治疗后外周血单核细胞在外周血单核细胞中的表达模式
5. Characterizing response patterns to ranibizumab therapy in patients with wet age-related macular degeneration: A latent class growth analysis [D] . Sun, Diana 2015

机译：潮湿年龄相关性黄斑变性患者的ranibizumab治疗的表征反应模式：潜在的增长分析
6. Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid 30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study) [O] . A T Fung, N Kumar, S K Vance, 2012

机译：评价玻璃体腔内抗VEGF治疗后持续/复发黄斑积液30天的患者中大剂量rAnibizumab2.0μmg在新生血管性黄斑变性管理中的作用的初步研究（LAST研究）
7. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration [O] . J H Vallance, B Johnson, M A Majid, 2010

机译：随机预期双掩盖探索性研究比较组合光动力处理和玻璃体内ranibizumab与玻璃体内Ranibizumab单一治疗治疗新生血管年龄相关性黄斑变性

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration

摘要

著录项

相似文献

相关主题

期刊订阅